REGADENOSON

Other

Brand names: Regadenoson

Intravenous

Mechanism of Action

12.1 Mechanism of Action Regadenoson is a low affinity agonist (K i ≈ 1.3 µM) for the A 2A adenosine receptor, with at least 10-fold lower affinity for the A 1 adenosine receptor (K i > 16.5 µM), and weak, if any, affinity for the A 2B and A 3 adenosine receptors. Activation of the A 2A adenosine receptor by regadenoson produces coronary vasodilation and increases coronary blood flow (CBF).

Indications

See full prescribing information

Contraindications

• 4 CONTRAINDICATIONS Do not administer regadenoson injection to patients with: Second- or third-degree AV block
• or · sinus node dysfunction unless the patients have a functioning artificial pacemaker (4) .

FDA Warnings

5 WARNINGS AND PRECAUTIONS Myocardial Ischemia
Fatal cardiac events have occurred
Avoid use in patients with symptoms or signs of acute myocardial ischemia, for example unstable angina or cardiovascular instability, who may be at greater risk
The risk of serious hypotension may be higher in patients with autonomic dysfunction, stenotic valvular heart disease, pericarditis or pericardial effusions, stenotic carotid artery disease with cerebrovascular insufficiency, or hypovolemia (5

Known Side Effects

8 documented side effects by frequency

Nausea

>10%

Shortness of Breath

1-10%

Vomiting

1-10%

Headache

1-10%

Low Blood Pressure

1-10%

Dizziness

1-10%

Chest Pain

1-10%

Tremor

0.1-1%

Community Discussions

No community discussions found for REGADENOSON yet.

Compare With

0 available comparisons

No comparisons yet.

Formulations

Dosage Forms

Tablet

Route

Intravenous